Overview


According to FutureWise analysis the market for antihypertensive drugs in 2023 is US$ 32.18 billion, and is expected to reach US$ 41.46 billion by 2031 at a CAGR of 3.20%.

Antihypertensive medications fall under several chemical classes and are used to treat, regulate, or prevent hypertension. Antihypertensive medication types differ from one another both structurally and therapeutically. With the rise of hypertension in the general population at 31% in the UK [defined by the National Institute for Health and Care Excellence (NICE) as a measurement of 140/90 mm Hg or higher in clinic, with subsequent ambulatory or home measurement of 135/85 mm Hg or higher], they are crucial in the practise of anaesthesia. Antihypertensive medications are frequently used for unrelated diseases, such as anxiety, thyrotoxicosis, or heart failure. Examples of these include ACEIs for heart failure and -blockers for thyrotoxicosis. Therefore, the medicine and its indication both have an impact on how anaesthetic is administered.

Hypertension, increases the risk of heart ailment and stroke. Hypertension risk factors include obesity, excessive alcohol use, smoking, and a family history. Beta-blockers are routinely used to treat hypertension. High blood pressure, also known as hypertension, is a frequent condition where the blood's long-term pressure against your artery walls is severe enough to potentially harm individual's and lead to coronary heart disease. Drugs for high blood pressure are used to treat patients who have the condition.

FutureWise Market Research has published a report that provides an insightful analysis of antihypertensive drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the antihypertensive drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.
  • Boehringer Ingelheim GmbH.
  • Merck KGaA.
  • Johnson and Johnson.
  • Bayer AG.
  • Pfizer, Inc.
  • Takeda Pharmaceutical Co.Ltd.
  • AstraZeneca plc.
  • Daiichi Sankyo Company.
  • Sanofi S.A.
  • Novartis International AG.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antihypertensive Drugs Market:

In May 2022-Hanmi Pharmaceutical announced that it will begin selling the popular hypertension medication Amosartan in China under the trade name Meiyaping. It represented the introduction of the first domestic blood pressure combination therapy to the Chinese market.

The increasing prevalence of hypertension worldwide is one of the main drivers of the expansion of the anti-hypertensive medicine market. The rise of hypertension has significantly increased over the past few years due to the major recognised causes of hypertension, which include kidney illnesses, diabetes, obstructive sleep disorders, and other cardiovascular diseases. Additionally, several medications can cause hypertension in people with other illnesses or problems, which is anticipated to expand the market. As of June 2021, cardiovascular diseases (CVDs) were the major cause of mortality globally, accounting for an estimated 17.9 million deaths, according to the World Health Organisation, a Swiss government agency in charge of global public health. Moreover, combination medications are now more frequently used in treatment than monotherapy. While combination therapy (the use of various drugs) allows for action on multiple hypertensive processes, monotherapy involves using a single medication to treat hypertension. When the two drugs are combined with different mechanisms of action, the effect is two to five times stronger than monotherapy. When two antihypertensive drugs with different mechanisms of action are combined, coronary events are reduced by 40% and cerebrovascular events by 54%, compared to a higher dose of monotherapy that reduces coronary events by 29% and cerebrovascular events by 40%. A target organ is therefore better protected when combination therapy is used than increasing the monotherapy dose. Therefore, combination therapy is more widely used, effective, and generally well-liked. This has allowed major players to further develop their product and grow their consumer base. However, the general lack of information regarding anti-hypertensive medications is one of the major barriers to market. First of all, the majority of people in developing nations do not get routine medical examinations and are unaware that they have hypertension until they exhibit severe symptoms. The fact that many individuals with hypertension do not follow their prescription schedule and stop taking it after 1-2 weeks until their symptoms emerge poses a significant challenge to the market for anti-hypertensive drugs.

By Therapeutic Class

  • Diuretics
  • ACE Inhibitors
  • Calcium Channel Blockers
  • Beta-adrenergic Blockers
  • Vasodilators
  • Others

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • E-commerce

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The main driver of the anti-hypertensive drug market expansion in the region is the increased prevalence of hypertension. The main factor boosting the expansion of the anti-hypertensive medicine industry in the region is the increased prevalence of hypertension. According to the Centres for Disease Control and Prevention Over half of adults (47 percent, or 116 million) will have hypertension by July 2022.Therefore, it is anticipated that the increased prevalence of hypertension in the US will raise demand for anti-hypertensive drugs, leading to market expansion. Identifying those who are predisposed to the disease, having a technologically advanced healthcare infrastructure, and managing the disease's prognosis are some other key market drivers of the North American anti-hypertension market.
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Antihypertensive Drugs Market, By therapeutic class, By distribution channel and By region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record and evaluate the competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antihypertensive Drugs Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global Antihypertensive Drugs Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antihypertensive Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Antihypertensive Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antihypertensive Drugs Market, By Therapeutic Class Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Diuretics
        2. ACE Inhibitors
        3. Calcium Channel Blockers
        4. Beta-adrenergic Blockers
        5. Vasodilators
        6. Others

  • 8.   Global Antihypertensive Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Retail Pharmacy
        2. Hospital Pharmacy
        3. E-commerce

  • 9.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)

    •   1. Boehringer Ingelheim GmbH,
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck KGaA
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Johnson and Johnson
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bayer AG
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Takeda Pharmaceutical Co., Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AstraZeneca plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Daiichi Sankyo Company
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi S.A.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Novartis International AG.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client

    •   


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11